Olaparib phase III SOLO-2 trial demonstrates significant PFS benefit in BRCA-mutated disease

Sanaz Memarzadeh receives $4.1M to develop immune therapies for ovarian cancer

Sanaz Memarzadeh of UCLA has received two grants totaling $4.1 million to develop advanced cell-based immune therapies for high-grade serous ovarian cancers that have become resistant to conventional treatments.

July 12, 2024

Vol.50 No.28

In Brief

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences have been awarded five grants from NCI in 2024, totaling $4.6 million.

June 28, 2024

Vol.50 No.26

Clinical

HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices

Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.

May 17, 2024

Vol.50 No.20

By Jacquelyn Cobb

Conversation with The Cancer Letter

NCI’s Lisa McShane: We need to understand the implications of HRD assay discordance

Homologous recombination deficiency tests are available from multiple vendors, and every day they are used to determine whether patients stand to benefit from PARP inhibitors.

May 17, 2024

Vol.50 No.20

By Jacquelyn Cobb

Funding Opportunities

DoD Ovarian Cancer Research Program anticipated funding opportunities for FY24

The FY24 Defense Appropriations Act is anticipated to provide funding for the Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members, and all women impacted by this disease.

April 05, 2024

Vol.50 No.14

In Brief

Shelley Tworoger named head of oncological science, associate director for population science at OHSU Knight

Shelley Tworoger, an epidemiologist at Moffitt Cancer Center, was named to two roles at OHSU: head of the Division of Oncological Sciences in the School of Medicine, and associate director for population science at the Knight Cancer Institute.

October 27, 2023

Vol.49 No.40

Olaparib phase III SOLO-2 trial demonstrates significant PFS benefit in BRCA-mutated disease

YOU MAY BE INTERESTED IN

Sanaz Memarzadeh receives $4.1M to develop immune therapies for ovarian cancer

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices

NCI’s Lisa McShane: We need to understand the implications of HRD assay discordance

DoD Ovarian Cancer Research Program anticipated funding opportunities for FY24

Shelley Tworoger named head of oncological science, associate director for population science at OHSU Knight

Renew today!

Subscriber content

Login